From Financial Modeling Prep: 2025-02-10 03:00:03

Incyte Corporation (NASDAQ:INCY) is known for its innovative therapies like Jakafi and Opzelura, treating conditions such as polycythemia vera and myelofibrosis. Analysts expect an EPS of $1.58 and revenue of $1.15 billion for the upcoming quarterly earnings release on February 11, 2025. Incyte’s stock has surged by 27.1% in the past year, outperforming the industry.

With a high valuation, Incyte has a P/E ratio of 439.62 and a price-to-sales ratio of 3.50. The company’s financial metrics indicate strong market performance, despite the high valuation. Incyte maintains a minimal debt-to-equity ratio of 0.012 and a current ratio of 1.87, showcasing its stable financial position for future growth in the biopharmaceutical sector.



Read more at Financial Modeling Prep:: Incyte Corporation’s Upcoming Quarterly Earnings: …